KR20240148350A - 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드 - Google Patents

화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드 Download PDF

Info

Publication number
KR20240148350A
KR20240148350A KR1020247027154A KR20247027154A KR20240148350A KR 20240148350 A KR20240148350 A KR 20240148350A KR 1020247027154 A KR1020247027154 A KR 1020247027154A KR 20247027154 A KR20247027154 A KR 20247027154A KR 20240148350 A KR20240148350 A KR 20240148350A
Authority
KR
South Korea
Prior art keywords
subject
months
period
administration period
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247027154A
Other languages
English (en)
Korean (ko)
Inventor
아리엘 테퍼
안드레아 마에스
마르셀라 베르가라
크리스티나 라미레즈
Original Assignee
인스메드 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스메드 인코포레이티드 filed Critical 인스메드 인코포레이티드
Publication of KR20240148350A publication Critical patent/KR20240148350A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247027154A 2022-02-16 2023-02-16 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드 Pending KR20240148350A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263310751P 2022-02-16 2022-02-16
US63/310,751 2022-02-16
PCT/US2023/062731 WO2023159120A1 (en) 2022-02-16 2023-02-16 Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Publications (1)

Publication Number Publication Date
KR20240148350A true KR20240148350A (ko) 2024-10-11

Family

ID=87579133

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247027154A Pending KR20240148350A (ko) 2022-02-16 2023-02-16 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드

Country Status (11)

Country Link
US (1) US20250144116A1 (https=)
EP (1) EP4479059A4 (https=)
JP (1) JP2025508359A (https=)
KR (1) KR20240148350A (https=)
CN (1) CN118695864A (https=)
AU (1) AU2023221393A1 (https=)
CA (1) CA3244131A1 (https=)
GB (1) GB2630719A (https=)
IL (1) IL314769A (https=)
MX (1) MX2024009995A (https=)
WO (1) WO2023159120A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) 2014-01-24 2018-02-24
KR20250002710A (ko) 2018-03-01 2025-01-07 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (https=) * 2014-01-24 2018-02-24
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
AU2019217870A1 (en) * 2018-02-07 2020-08-27 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating ANCA associated vasculitides
WO2020214855A1 (en) * 2019-04-17 2020-10-22 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
EP4561565A2 (en) * 2022-07-28 2025-06-04 Insmed Incorporated Novel dpp1 inhibitors and uses thereof

Also Published As

Publication number Publication date
GB2630719A (en) 2024-12-04
AU2023221393A1 (en) 2024-08-15
EP4479059A4 (en) 2026-01-28
WO2023159120A1 (en) 2023-08-24
GB202412566D0 (en) 2024-10-09
IL314769A (en) 2024-10-01
JP2025508359A (ja) 2025-03-26
US20250144116A1 (en) 2025-05-08
MX2024009995A (es) 2024-08-22
CA3244131A1 (en) 2023-08-24
EP4479059A1 (en) 2024-12-25
CN118695864A (zh) 2024-09-24

Similar Documents

Publication Publication Date Title
KR20240148350A (ko) 화농성한선염을 치료하기 위한 특정 n-(1-시아노-2-페닐에틸)-1,4-옥사제판-2-카르복스아미드
Camras et al. Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery
US20250049813A1 (en) Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
US9572801B2 (en) Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
JP7480131B2 (ja) （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
JP2003523948A (ja) アミロイドβ前駆体障害の治療法
AU2022245186A1 (en) Treatment of hidradenitis suppurativa with orismilast
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
JP2011518828A (ja) 眼球障害の処置のためのｐａｉ−１の発現および活性インヒビター
JP7696006B2 (ja) 化膿性汗腺炎の治療における使用のためのレミブルチニブ
CN117919231A (zh) 用于预防和治疗糖尿病心肌病的化合物及其应用
US20260069578A1 (en) Treatment of neutrophilic dermatoses
BRPI0713647A2 (pt) formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios
JP2022544834A (ja) 肺疾患における好中球エラスターゼ阻害剤の使用
NL2036681B1 (en) Application of Naringin Combined with Rapamycin in the Preparation of Medications for Treating Hyperlipidemia
US20260108483A1 (en) Methods and compositions for preventing the progression of diabetic retinopathy and related conditions
US12409172B2 (en) Dosage regimen
JP2026069500A (ja) 線維症を治療するためのシクロスポリン類似体の使用
CN121796375A (zh) 用于预防和治疗糖尿病心肌病的化合物及其应用
AU2024278948A1 (en) Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness
HK40003409A (en) Treatment of prurigo nodularis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000